Get started
Sarepta Therapeutics, Inc.Sarepta Therapeutics, Inc.Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options Bonds

SRPT chart


Full chart

SRPT upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪4.95 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
21.41
Basic EPS (TTM)
2.46 USD
Net income (FY)
‪235.24 M‬ USD
Revenue (FY)
‪1.90 B‬ USD
Shares float
‪91.14 M‬
Beta (1Y)
1.22

Employees


Employees (FY)
‪1.37 K‬
Change (1Y)
+58 +4.41%
Revenue / Employee (1Y)
‪1.39 M‬ USD
Net income / Employee (1Y)
‪171.46 K‬ USD

About Sarepta Therapeutics, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Douglas S. Ingram
Website
sarepta.com
Headquarters
Cambridge
Founded
1980
FIGI
BBG000BCJ161
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

SRPT news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

SRPT highest yielding bonds


SRPT5657414
Sarepta Therapeutics, Inc. 1.25% 15-SEP-2027
Yield to maturity
4.95%
Maturity date
Sep 15, 2027

See all SRPT bonds 

Sparks


Curated watchlists where SRPT is featured.

See all sparks 


Check out other big names from the same industry as SRPT.

Frequently Asked Questions


The current price of SRPT is 54.63 USD — it has increased by 1.50% in the past 24 hours. Watch Sarepta Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Sarepta Therapeutics, Inc. stocks are traded under the ticker SRPT.
SRPT stock has risen by 0.40% compared to the previous week, the month change is a −47.68% fall, over the last year Sarepta Therapeutics, Inc. has showed a −56.00% decrease.
We've gathered analysts' opinions on Sarepta Therapeutics, Inc. future price: according to them, SRPT price has a max estimate of 209.00 USD and a min estimate of 70.00 USD. Watch SRPT chart and read a more detailed Sarepta Therapeutics, Inc. stock forecast: see what analysts think of Sarepta Therapeutics, Inc. and suggest that you do with its stocks.
SRPT reached its all-time high on Dec 22, 2020 with the price of 181.83 USD, and its all-time low was 2.60 USD and was reached on May 18, 2012. View more price dynamics on SRPT chart.
See other stocks reaching their highest and lowest prices.
SRPT stock is 7.02% volatile and has beta coefficient of 1.22. Track Sarepta Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Sarepta Therapeutics, Inc. there?
Today Sarepta Therapeutics, Inc. has the market capitalization of ‪5.30 B‬, it has decreased by −15.36% over the last week.
Yes, you can track Sarepta Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Sarepta Therapeutics, Inc. is going to release the next earnings report on Apr 30, 2025. Keep track of upcoming events with our Earnings Calendar.
SRPT earnings for the last quarter are 1.50 USD per share, whereas the estimation was 1.88 USD resulting in a −20.32% surprise. The estimated earnings for the next quarter are −3.11 USD per share. See more details about Sarepta Therapeutics, Inc. earnings.
Sarepta Therapeutics, Inc. revenue for the last quarter amounts to ‪658.41 M‬ USD, despite the estimated figure of ‪627.59 M‬ USD. In the next quarter, revenue is expected to reach ‪687.47 M‬ USD.
SRPT net income for the last quarter is ‪159.05 M‬ USD, while the quarter before that showed ‪33.61 M‬ USD of net income which accounts for 373.21% change. Track more Sarepta Therapeutics, Inc. financial stats to get the full picture.
No, SRPT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 15, 2025, the company has ‪1.37 K‬ employees. See our rating of the largest employees — is Sarepta Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Sarepta Therapeutics, Inc. EBITDA is ‪271.97 M‬ USD, and current EBITDA margin is 14.30%. See more stats in Sarepta Therapeutics, Inc. financial statements.
Like other stocks, SRPT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Sarepta Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Sarepta Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Sarepta Therapeutics, Inc. stock shows the strong sell signal. See more of Sarepta Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.